Prime Health Services to Cover GenomeDx's Prostate Cancer Risk Test | GenomeWeb

NEW YORK (GenomeWeb) – GenomeDx today announced an agreement with Prime Health Services providing coverage of GenomeDx's prostate cancer test.

Under the terms of the deal, the test, called Decipher, will be covered by Prime Health for patients whose physicians order it. Prime Health's network includes 9 million covered lives and brings the total number of covered lives for Decipher to about 120 million, GenomeDx said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.